Pharmaceutical

Crossject secures funding from French Government for needle-free platform

The cash injection will accelerate the development of Crossject’s prefilled needle free platform to treat anaphylactic shock.

Jul 14, 2024 - 04:00
Crossject secures funding from French Government for needle-free platform
The cash injection will accelerate the development of Crossject’s prefilled needle free platform to treat anaphylactic shock.
Read the original article

Tags:

Previous Article

Microbeads with adaptable fluorescent colors from visible light to near-infrared

Next Article

MSD closes $1.3bn EyeBio acquisition, plans pivotal trial for lead asset

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

NIH begins long-delayed clinical trials for long Covid, announces new research office

NIH begins long-delayed clinical trials for long Covid,...

Aug 1, 2023

STAT+: Pharmalittle: A not-so-new Biogen?; ALS Association and 15 chapters part ways over organizational clashes

STAT+: Pharmalittle: A not-so-new Biogen?; ALS Associat...

Jun 14, 2023

STAT+: Biden invokes Defense Production Act to stem drug shortages

STAT+: Biden invokes Defense Production Act to stem dru...

Nov 29, 2023